07:00 , Apr 3, 2006 |  BC Week In Review  |  Company News

Threshold management update

Threshold Pharmaceuticals Inc. (THLD), Redwood City, Calif.   Business: Cancer, Genitourinary   Hired: Michael Brawer as urology therapeutic area head, formerly a company consultant; Hassan Movahhed as VP of clinical affairs, formerly senior director of...
08:00 , Mar 21, 2005 |  BC Week In Review  |  Company News

Anosys, Chromos deal

CHR signed a letter of intent to acquire Anosys for stock, warrants and convertible notes. Both companies develop compounds for cancer and infectious disease. CHR will issue Anosys shareholders a C$2.1 million (US$1.7 million) convertible...
08:00 , Feb 28, 2005 |  BC Week In Review  |  Company News

Anosys, Avidex deal

Under a previous deal, the companies used Avidex's soluble T cell receptors to validate T cell antigen expression on Anosys' Dexosome cancer vaccine candidates. Anosys' lead candidate has completed Phase I trials for melanoma and...
07:00 , Sep 15, 2003 |  BC Week In Review  |  Company News

Anosys, Epimmune deal

EPMN received an undisclosed milestone payment from Anosys under a 2001 deal in which Anosys non-exclusively licensed, outside Japan, EPMN's universal breast, colon, lung and prostate antigens for ex vivo cancer therapies. The payment was...
07:00 , Aug 18, 2003 |  BC Week In Review  |  Company News

Anosys, Epimmune deal

The companies terminated their previously announced merger. EPMN said the companies had concluded that conditions did not support the concept of a combined company. At the time of the February merger announcement, the companies said...
07:00 , Aug 12, 2003 |  BC Extra  |  Company News

Epimmune, Anosys merger terminated

EPMN and Anosys (Menlo Park, Calif.) terminated their previously announced merger. EPMN said the companies concluded that conditions did not support the concept of the combined company. At the time of the February merger announcement,...
08:00 , Feb 17, 2003 |  BC Week In Review  |  Company News

Epimmune, Anosys deal

EPMN and cancer vaccine company Anosys said they will merge in an all stock transaction. The combined company will bring together EPMN's epitope technology and Anosys' exosome delivery technology and focus on immunotherapeutics to treat...
08:00 , Feb 13, 2003 |  BC Extra  |  Company News

Epimmune, Anosys to merge

EPMN and cancer vaccine company Anosys (Menlo Park, Calif.) said they will merge in an all stock transaction. The combined company will bring together EPMN's epitope technology and Anosys' exosome delivery technology and focus on...
08:00 , Oct 28, 2002 |  BC Week In Review  |  Clinical News

Dexosome-based cancer vaccine: Phase II

Anosys disclosed that it started in July a U.S. Phase II study of its dexosome-based cancer vaccine in 60 melanoma patients. Anosys Inc. , Menlo Park, Calif.   Product: Dexosome-based cancer vaccine   Business: Cancer...
08:00 , Oct 28, 2002 |  BC Week In Review  |  Clinical News

Dexosome-based cancer vaccine: Phase I

In a French Phase I study in 6 patients with stage III or IV melanoma treated with the vaccine, 2 patients had prolonged disease stabilization and 1 patient had tumor shrinkage. A CTL response was...